ReviewCurrent atherosclerosis reports2016
Approach to Statin Use in 2016: an Update.
Review in Current atherosclerosis reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 33 citations in OpenAlex.
- Statin-induced debilitating weakness and myopathy.BMJ case reports · 2024Article
- Potential Benefits and Risks Associated with the Use of Statins.Pharmaceutics · 2024 · on this mapReview
- Predictive Value ofGenes · 2023Article
- Association between Statin Use and Risk of Parkinson's Disease: Evidence from 18 Observational Studies Comprising 3.7 Million Individuals.Journal of personalized medicine · 2022Article
- Review
- Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Exclusive and Combined Use of Statins and Aspirin and the Risk of Pancreatic Cancer: a Case-Control Study.Scientific reports · 2017Article
- Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia.Scientific reports · 2017Article
- Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statin therapy is the pharmacologic foundation of cholesterol treatment and the most common class of medication prescribed in the USA. The clinical benefits of statins and their favorable side effect profile have been well established for atherosclerotic cardiovascular disease prevention. With new guidelines on the treatment of dyslipidemia being published in the last several years, a greater percentage of the population now appears eligible for statin therapy. In this review, we discuss the updated American College of Cardiology/American Heart Association and National Lipid Association guidelines on lipid treatment, both of which endorse the importance of shared decision making and patient-centered care. We discuss factors beyond traditional risk factors that may be useful in refining risk-based decision making. Furthermore, we summarize the available statins, their potential benefits and limitations, and recent evidence on safety and tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.